BriaCell Expands Phase 3 Breast Cancer Trial with Penn Medicine’s Abramson Cancer Center
Event summary
- BriaCell adds Penn Medicine’s Abramson Cancer Center as a clinical site in its pivotal Phase 3 breast cancer study.
- Other recently activated sites include Indiana University, UVA, Baptist Health South Florida, and SCRI Oncology Partners.
- The Phase 3 Bria-ABC study evaluates Bria-IMT™ in combination with an immune checkpoint inhibitor versus physician’s choice of treatment in advanced breast cancer.
- Interim analysis of the study will be conducted after 144 patient events, with overall survival (OS) as the primary endpoint.
- Bria-IMT combination regimen has received FDA Fast Track designation.
The big picture
BriaCell’s expansion of its Phase 3 trial to include Penn Medicine’s Abramson Cancer Center underscores the growing interest in its immunotherapy regimen for advanced breast cancer. The inclusion of the trial in Nature Medicine’s article highlights its potential to shape future cancer treatments. The strategic addition of leading cancer centers aims to broaden access to the Bria-IMT regimen, addressing a significant unmet medical need in metastatic breast cancer.
What we're watching
- Trial Momentum
- Whether the addition of high-profile cancer centers will accelerate patient enrollment and interim analysis timing.
- Regulatory Pathway
- How the FDA Fast Track designation will influence the development and approval process for Bria-IMT.
- Clinical Efficacy
- The pace at which interim data will demonstrate the efficacy of Bria-IMT in combination with immune checkpoint inhibitors.
Related topics